Galectin Gross Profit from 2010 to 2024

GALT Stock

USD 1.04 0.96 48.00%

Galectin Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit will likely drop to about -34.6 K in 2024. Gross Profit is the profit Galectin Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2001-03-31

Previous Quarter

-9 K

Current Value

-9 K

Quarterly Volatility

668.6 K

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 40 M, Interest Expense of 2.7 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.

Check out the analysis of Galectin Therapeutics Correlation against competitors.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Latest Galectin Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Galectin Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Galectin Therapeutics minus its cost of goods sold. It is profit before Galectin Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Galectin Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Galectin Gross Profit Regression Statistics

	Arithmetic Mean	(484,977)
	Geometric Mean	0.00
	Coefficient Of Variation	(374.39)
	Mean Deviation	875,070
	Median	(7,000)
	Standard Deviation	1,815,683
	Sample Variance	3.3T
	Range	7M
	R-Value	0.43
	Mean Square Error	2.9T
	R-Squared	0.18
	Significance	0.11
	Slope	172,909
	Total Sum of Squares	46.2T

Galectin Gross Profit History

	2024	-34.6 K
	2023	-33 K
	2022	-32 K
	2021	-41 K
	2020	-36 K
	2019	-35 K

Other Fundumenentals of Galectin Therapeutics

Gross Profit Margin

Galectin Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.25	-0.32	-0.5	0.25	0.2	1.0	-0.51	0.68	-0.03	-0.46	0.01	0.33	0.69	0.79	0.78	-0.67
Total Stockholder Equity	0.25		-0.99	0.55	-0.83	-0.89	0.26	-0.11	-0.22	0.31	0.03	0.75	0.94	-0.27	0.06	0.12	0.35
Net Debt	-0.32	-0.99		-0.52	0.8	0.86	-0.33	0.18	0.18	-0.26	-0.03	-0.77	-0.94	0.23	-0.09	-0.15	-0.32
Retained Earnings	-0.5	0.55	-0.52		-0.83	-0.8	-0.49	0.39	-0.89	0.24	0.6	0.58	0.56	-0.89	-0.6	-0.54	0.83
Accounts Payable	0.25	-0.83	0.8	-0.83		0.97	0.24	-0.04	0.56	-0.26	-0.34	-0.86	-0.7	0.61	0.39	0.33	-0.71
Total Liab	0.2	-0.89	0.86	-0.8	0.97		0.19	-0.11	0.52	-0.31	-0.25	-0.83	-0.78	0.57	0.33	0.27	-0.68
Total Current Assets	1.0	0.26	-0.33	-0.49	0.24	0.19		-0.51	0.67	-0.03	-0.45	0.02	0.34	0.68	0.79	0.78	-0.66
Short Term Debt	-0.51	-0.11	0.18	0.39	-0.04	-0.11	-0.51		-0.42	0.55	0.47	-0.1	-0.02	-0.33	-0.34	-0.35	0.25
Common Stock	0.68	-0.22	0.18	-0.89	0.56	0.52	0.67	-0.42		0.01	-0.56	-0.21	-0.28	0.99	0.76	0.71	-0.86
Property Plant Equipment	-0.03	0.31	-0.26	0.24	-0.26	-0.31	-0.03	0.55	0.01		0.32	0.19	0.33	0.04	0.27	0.3	-0.04
Current Deferred Revenue	-0.46	0.03	-0.03	0.6	-0.34	-0.25	-0.45	0.47	-0.56	0.32		0.2	0.11	-0.5	-0.3	-0.28	0.34
Net Receivables	0.01	0.75	-0.77	0.58	-0.86	-0.83	0.02	-0.1	-0.21	0.19	0.2		0.57	-0.26	-0.22	-0.2	0.43
Net Tangible Assets	0.33	0.94	-0.94	0.56	-0.7	-0.78	0.34	-0.02	-0.28	0.33	0.11	0.57		-0.28	0.13	0.2	0.3
Capital Surpluse	0.69	-0.27	0.23	-0.89	0.61	0.57	0.68	-0.33	0.99	0.04	-0.5	-0.26	-0.28		0.76	0.7	-0.88
Net Invested Capital	0.79	0.06	-0.09	-0.6	0.39	0.33	0.79	-0.34	0.76	0.27	-0.3	-0.22	0.13	0.76		0.99	-0.86
Net Working Capital	0.78	0.12	-0.15	-0.54	0.33	0.27	0.78	-0.35	0.71	0.3	-0.28	-0.2	0.2	0.7	0.99		-0.8
Capital Stock	-0.67	0.35	-0.32	0.83	-0.71	-0.68	-0.66	0.25	-0.86	-0.04	0.34	0.43	0.3	-0.88	-0.86	-0.8

Click cells to compare fundamentals

About Galectin Therapeutics Financial Statements

Galectin Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Gross Profit	-33 K	-34.6 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC